Kenvue (NYSE:KVUE) shares rose more than 5% intra-day today after the company delivered stronger-than-expected second-quarter results, but tempered its full-year outlook to reflect the impact of tariffs and currency pressures.
The consumer health company reported adjusted earnings per share of $0.24, edging past the $0.23 consensus estimate. Revenue totaled $3.74 billion, also ahead of the $3.68 billion forecast.
For fiscal 2025, the company now expects total net sales to grow 1% to 3% year-over-year. Organic sales growth is forecast between 2% and 4%, partially offset by a projected 1% drag from foreign exchange. Kenvue also warned that its adjusted operating income margin will decline from the prior year due to anticipated tariff costs.